TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of “Hold” by Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has been given an average recommendation of “Hold” by the four research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $11.00.

TLSI has been the subject of a number of analyst reports. Wall Street Zen downgraded TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Canaccord Genuity Group raised their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock opened at $4.99 on Friday. The stock has a market cap of $249.30 million, a PE ratio of -2.47 and a beta of 0.43. The firm has a fifty day moving average price of $6.38 and a 200 day moving average price of $5.25. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The business had revenue of $11.57 million during the quarter, compared to the consensus estimate of $11.76 million. As a group, equities analysts expect that TriSalus Life Sciences will post -1.55 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TLSI. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at approximately $29,000. JPMorgan Chase & Co. grew its position in shares of TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth about $47,000. Sequoia Financial Advisors LLC acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth about $90,000. Finally, New York State Common Retirement Fund purchased a new position in shares of TriSalus Life Sciences in the second quarter valued at approximately $108,000. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.